Nebenwirkungen · Bekemv
BEKEMV 300 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-148438 · Präparat HOS-099910
Table 1 gives the adverse reactions observed from spontaneous reporting and in eculizumab completed clinical trials, including PNH, aHUS, refractory gMG and NMOSD studies. Adverse reactions reported at a very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000) or not known (cannot be estimated from the available data) frequency with eculizumab, are listed by system organ class and preferred term. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-15T13:22:00Z · SHA-256 d387d4b9d5a9018b26548a18de1ddda14618dff713302b935763ed70f39b9ee1 · Passage badca1898e4a0e086667124cf5dad6a5313fc6b3042f837abf64c936510d388b · Zeichen 510–1066 im Abschnitt